1. Home
  2. BATL vs HBIO Comparison

BATL vs HBIO Comparison

Compare BATL & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Battalion Oil Corporation

BATL

Battalion Oil Corporation

N/A

Current Price

$1.05

Market Cap

28.8M

Sector

Energy

ML Signal

N/A

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

N/A

Current Price

$8.13

Market Cap

26.5M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
BATL
HBIO
Founded
1987
1901
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Laboratory Analytical Instruments
Sector
Energy
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
28.8M
26.5M
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
BATL
HBIO
Price
$1.05
$8.13
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 3.4M
14.8K
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 42.56
N/A
EPS
N/A
★ N/A
Revenue
★ $166,043,000.00
$116,176,000.00
Revenue This Year
N/A
$3.76
Revenue Next Year
N/A
$5.29
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.00
$0.38
52 Week High
$29.70
$8.40

Technical Indicators

Market Signals
Indicator
BATL
HBIO
Relative Strength Index (RSI) 31.38 N/A
Support Level N/A N/A
Resistance Level $1.29 N/A
Average True Range (ATR) 0.05 0.00
MACD -0.01 0.00
Stochastic Oscillator 2.78 0.00

Price Performance

Historical Comparison
BATL
HBIO

About BATL Battalion Oil Corporation

Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.

Share on Social Networks: